The DOI matches its Crossref record; 134 of the 134 references it cites were found in a registry or an index; none of the 272 sources its claims cite is checked for support yet.
Islet cell failure in type 2 diabetes
Open accessAbstract
The major focus of this Review is on the mechanisms of islet beta cell failure in the pathogenesis of obesity-associated type 2 diabetes (T2D). As this demise occurs within the context of beta cell compensation for insulin resistance, consideration is also given to the mechanisms involved in the compensation process, including mechanisms for expansion of beta cell mass and for enhanced beta cell performance. The importance of genetic, intrauterine, and environmental factors in the determination of "susceptible" islets and overall risk for T2D is reviewed. The likely mechanisms of beta cell failure are discussed within the two broad categories: those with initiation and those with progression roles.
Overview
CoChat Summary
## TL;DR
This is a 2006 review arguing that type 2 diabetes develops when insulin-resistant islets can no longer sustain compensatory b cell function, leading first to dysfunction and then progressive loss of b cell mass. It emphasizes that “susceptible” islets are shaped by genetic, intrauterine, and environmental factors, and that hyperglycemia accelerates damage through glucotoxic and glucolipotoxic mechanisms.
## Key findings
- In longitudinal studies, insulin levels rise during the normoglycemic and prediabetes phases and then decline when fasting glycemia exceeds the upper normal limit of 5.5 mM, marking b cell failure.
- A longitudinal study in Pima Indians found that b cell dysfunction was the major determinant of progression from normoglycemia to diabetes.
- In autopsy pancreata from 124 subjects, the paper reports a 40% and 63% loss of islet b cell volume in obese subjects with impaired fasting glucose and T2D, respectively, compared with weight-matched controls; lean T2D subjects had a 41% loss versus lean controls.
- The paper reports that the STOP-NIDDM trial showed acarbose treatment of IGT subjects reduced the risk of progression to diabetes by 36%.
## Methods
- Narrative review of mechanistic, animal, human postmortem, genetic, and epidemiologic studies on islet b cell compensation and failure in obesity-associated T2D.
- Synthesizes findings from rodent models (including ZF, ZDF, DBA2, GK, and IUGR models) and human islet/pancreas studies, including a transcript profiling study of 7 normal and 5 T2D human islet samples.
- Main analysis is integrative and conceptual: it organizes evidence into mechanisms that promote compensation and mechanisms with initiation versus progression roles in b cell failure.
## Limitations
- The paper states that the mechanisms of b cell compensation are “not fully understood,” and that the role of several proposed factors remains to be established or warrants further investigation.
- It explicitly notes uncertainty about several mechanisms, including whether nonimmune islet inflammation contributes in vivo, whether IAPP is causal in b cell dysfunction and demise, and whether reduced ARNT expression is an early defect or a consequence.
- Evident from the text: this is a review, not a new experimental study, so its conclusions depend on the quality and consistency of the cited animal and human studies rather than on a single primary dataset.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 164 Not checked · 38 Own results and interpretations
In the paper
“Longitudinal studies of subjects that develop T2D show a rise in insulin levels in the normoglycemic and prediabetes phases that keep glycemia near normal despite the insulin resistance ( b cell compensation), followed by a decline when fasting glycemia surpasses the upper limit of normal of 5.5 mM ( b cell failure) (5) (Figure 1).”
What the sources say
- Not checked yetcites [5]
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“With respect to the latter, increases were observed in enzymes and metabolites involved in anaplerosis and the malate-pyruvate and citratepyruvate shuttles of ZF islets (12).”
What the sources say
- Not checked yetcites [12]
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Inhibition of these pathways by phenylacetic acid, which inhibits PC, markedly impeded GSIS (12).”
What the sources say
- Not checked yetcites [12]
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Studies of islet b cell compensation within models that maintain normoglycemia show upregulation of glucose metabolism pathways (12, 13, 31).”
What the sources say
- Not checked yetcites [12]
- Not checked yetcites [13]
- Not checked yetcites [31]
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“A recent study in Zucker fatty (ZF) rats has provided strong support for PKB activation in the b cell growth response to insulin resistance in this normoglycemic model (11).”
What the sources say
- Not checked yetcites [11]
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
116 more claims
Create a free account to see all 203 claims and to verify the 272 references still open.
- It may state two separate claims as one. 71
- Probably not a substantial claim. 13
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Importantly, several of these studies have demonstrated that fatty acids do not induce beta-cell dysfunction in the absence of elevated glucose, highlighting that fatty acids and glucose are not cytotoxic independently.168,169”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [169]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Notably, impairment of insulin secretion in the presence of an intact β-cell mass also occurs in the early stages of human age-related diabetes123.”
From The telomere syndromes (2012) · cites this paper as [123]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Minor deficiencies in the β-cell machinery may only be exposed in times of metabolic stress, such as pregnancy [75].”
From The Pathophysiology of Gestational Diabetes Mellitus (2018) · cites this paper as [75]
Experimental — accuracy not yet measured
Citations
Cites
Mootha, V. K., Lindgren, C. M., Eriksson, K.-F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., et al. (2003) · Nature Genetics · doi:10.1038/ng1180 · Cited by 10,197
Global and societal implications of the diabetes epidemic
Zimmet, P., Alberti, K. G. M. M., & Shaw, J. (2001) · Nature · doi:10.1038/414782a · Cited by 5,883
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial
Chiasson, J.-L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., & Laakso, M. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08905-5 · Cited by 2,543
Barker, D. J. P., Hales, C. N., Fall, C. H. D., Osmond, C., Phipps, K., & Clark, P. M. S. (1993) · Diabetologia · doi:10.1007/bf00399095 · Cited by 2,468
Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes
Grant, S. F. A., Thorleifsson, G., Reynisdottir, I., Benediktsson, R., Manolescu, A., Sainz, J., Helgason, A., Stefansson, H., Emilsson, V., Helgadottir, A., et al. (2006) · Nature Genetics · doi:10.1038/ng1732 · Cited by 2,287
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Mitochondrial dysfunction and type 2 diabetes
Lowell, B. B., & Shulman, G. I. (2005) · Science · doi:10.1126/science.1104343 · Cited by 2,070
Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase
Minokoshi, Y., Kim, Y.-B., Peroni, O. D., Fryer, L. G. D., Müller, C., Carling, D., & Kahn, B. B. (2002) · Nature · doi:10.1038/415339a · Cited by 2,053
Weyer, C., Bogardus, C., Mott, D. M., & Pratley, R. E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7231 · Cited by 1,940
Cited by
Type 2 diabetes as an inflammatory disease
Donath, M. Y., & Shoelson, S. E. (2011) · Nature Reviews Immunology · doi:10.1038/nri2925 · Cited by 3,737
DeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
The Pathophysiology of Gestational Diabetes Mellitus
Plows, J. F., Stanley, J. L., Baker, P. N., Reynolds, C. M., & Vickers, M. H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113342 · Cited by 1,874
“Minor deficiencies in the β-cell machinery may only be exposed in times of metabolic stress, such as pregnancy [75].”
BackgroundMoringa oleifera: A review on nutritive importance and its medicinal application
Gopalakrishnan, L., Doriya, K., & Kumar, D. S. (2016) · Food Science and Human Wellness · doi:10.1016/j.fshw.2016.04.001 · Cited by 1,374
The Role for Endoplasmic Reticulum Stress in Diabetes Mellitus
Eizirik, D. L., Cardozo, A. K., & Cnop, M. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0015 · Cited by 1,173
Metadata
- Authors
- Prentki, M.
- Affiliations
- Centre Hospitalier de l’Université de Montréal (CA)
- Corresponding author
- Prentki, M.
- ORCID
- Prentki, M.
- Venue
- Journal of Clinical Investigation
- Published
- 2006-07-03
- Volume
- 116
- Issue
- 7
- Pages
- 1802-1812
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1483155
- OpenAlex
- W1598254642
- Cited by
- 1,690
- References
- 132
- Citations by year
- 2026: 52 · 2025: 52 · 2024: 46 · 2023: 54 · 2022: 68 · 2021: 95 · 2020: 95 · 2019: 111 · 2018: 90 · 2017: 109 · 2016: 112 · 2015: 107 · 2014: 131 · 2013: 97 · 2012: 98
- FWCI
- 13.11
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- ANU Open Research (Australian National University) (submittedVersion)
- Funders
- ACT Government
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK063356, DK63356)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- beta-cell failure, type 2 diabetes, obesity, beta-cell compensation, beta-cell mass expansion, insulin resistance, genetic susceptibility, intrauterine factors, environmental risk factors, beta-cell dysfunction
- MeSH terms
- Animals, Diabetes Mellitus, Type 2, Humans, Insulin Resistance, Disease Progression, Genetic Predisposition to Disease, Insulin-Secreting Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Islet cell failure in type 2 diabetes. https://app.cochat.ai/papers/10.1172/jci29103
- The paper
- Prentki, M. (2006). Islet cell failure in type 2 diabetes. Journal of Clinical Investigation. https://doi.org/10.1172/jci29103
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.